IL1B and COVID-19: Anti-malarial drugs hydroxychloroquine and chloroquine that are know to decrease Th17-related cytokines; IL-6, IL-17, IL-22, TNFα and IL-1β have been evaluated for efficacy in COVID-19 treatment in several clinical trials (Felsenstein et al., 2020; da Silva et al., 2020; Karres et al., 2020; Meo et al., 2020).